Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A study to evaluate if dapagliflozin can prevent the gradual loss of kidney function and improve survival for patients with chronic kidney disease. Badanie oceniające, czy dapagliflozyna może zapobiec stopniowej utracie czynności nerek i wydłużyć przeżycie pacjentów z przewlekła chorobą nerek
To determine if dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of ≥50% sustained decline in estimated glomerular filtration rate (eGFR), reaching end ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive
to investigate the safety of Entocort™ EC (budesonide) in a paediatric mild to moderate Crohn’s disease population for maintenance of clinical remission
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca Oy
Update Il y a 4 ans
Centralised Pan-European Survey on the Undertreatment of Hyperchlesterolemia
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines, overall and by country.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Olaparib in gBRCA Mutated Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Olaparib en cáncer de páncreas metastásico con mutación de gBRCA cuya enfermedad no ha progresado con una quimioterapia de primera línea basada en el platino
To determine the efficacy of Olaparib maintenance monotherapy compared to placebo by progression free survival (PFS) Determinar la eficacia de la monoterapia de mantenimiento con olaparib en com...
Country
None
organs
None
Specialty
None
unknown
More information
AstraZeneca (South Africa)
Update Il y a 4 ans
Quetiapine augmentation of a serotonin reuptake inhibitor in treatment resistant obsessive-compulsive disorder: a multi-site, placebo-controlled study
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monotherapy in the Maintenance Treatment of Patients with Generalised Anxiety Disorder Following an Open-Label Stabilisation Period (PLATINUM STUDY)
The primary objective of the study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Generalised Anxiety Diso...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhalations of Ventoline 100μg, and placebo, delivered by pressurised metered dose inhalers, in patients with chronic obstructive pulmonary disease (COPD)
To evaluate efficacy i.e. to study the bronchodilatating effect within the first 180 minutes after two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μg, two inhala...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Efficacy of TC-5214 compared with placebo as an adjunct to antidepressant (selective serotonin reuptake inhibitor SSRI]/serotonin/norepinephrine reuptake inhibitor [SNRI]) therapy in patients with maj...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel Syndrome
The primary objective of this study is to evaluate the effect of AZD7371 20 mg bid, AZD7371 5 mg bid and placebo on rectal sensitivity during rectal distension by assessment of discomfort by using a n...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen
The primary objective of this study is to assess the efficacy of ZD6474 (100 mg and 300 mg) in combination with FOLFIRI versus FOLFIRI alone for the treatment of patients with colorectal cancer that ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next